The effect of adjuvant chemotherapy on survival in Korean patients with node negative T1c, triple negative breast cancer
The present study investigated the prognostic role of adjuvant systemic chemotherapy in patients with node negative, T1c triple negative breast cancer (TNBC) from a nationwide cohort. In addition, the prognostic effect between 3 different chemotherapy regimens were compared in node-negative T1c TNBC...
Gespeichert in:
| Veröffentlicht in: | PloS one 2018-05, Vol.13 (5), p.e0197523-e0197523 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e0197523 |
|---|---|
| container_issue | 5 |
| container_start_page | e0197523 |
| container_title | PloS one |
| container_volume | 13 |
| creator | Lim, Seung Taek Park, Chan Heun Kim, Sung Yong Nam, Seok Jin Kang, Eun Young Moon, Byung-In Lee, Hyouk Jin Jeon, Ye Won Gwak, Hongki Suh, Young Jin |
| description | The present study investigated the prognostic role of adjuvant systemic chemotherapy in patients with node negative, T1c triple negative breast cancer (TNBC) from a nationwide cohort. In addition, the prognostic effect between 3 different chemotherapy regimens were compared in node-negative T1c TNBC patients by subgroup analysis.
From the Korean breast cancer registry database, 1,151 T1c node negative TNBC patients were included in this study. Patients were categorized into four treatment groups according to chemotherapy regimen: (1) no chemotherapy, (2) adriamycin plus cyclophosphamide (AC), (3) adriamycin/epirubicin plus cyclophosphamide plus 5-FU (FAC/FEC), and (4) cyclophosphamide plus 5-FU plus methotrexate (CMF). Overall survival (OS) was evaluated between each patient group.
Of the 1,151 T1c node negative TNBC patients, 1,006 received adjuvant chemotherapy, while 145 received no chemotherapy. Among the patients receiving adjuvant chemotherapy the distribution of regimens was: 586 AC, 168 FAC/FEC (126 FAC, 42 FEC), and 252 CMF. The mean follow-up time of the full study cohort was 87.98 ± 33.56 months (range = 6-192 months). Patients in the no chemotherapy group showed significantly worse OS compared to each chemotherapy regimen group. However, when OS was compared between each chemotherapy regimen, no significant difference was found.
This study showed that adjuvant systemic chemotherapy improved OS in T1c node negative TNBC patients, regardless of chemotherapy between AC, FAC/FEC, and CMF regimens. |
| doi_str_mv | 10.1371/journal.pone.0197523 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_2039842462</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A538952537</galeid><doaj_id>oai_doaj_org_article_606d06f1f66f4cc1a30fe05af1dafb9a</doaj_id><sourcerecordid>A538952537</sourcerecordid><originalsourceid>FETCH-LOGICAL-c692t-f453374281be1dbc81c4f49418507417422e190cf69ca892a690f9d8dc446b703</originalsourceid><addsrcrecordid>eNqNk1-L1DAUxYso7rr6DUQDgig4Y9KmafMiLIt_BhcWdPQ1ZNKbaYZOUpN03P32ZpzuMpV9kDw03PzOSXKam2XPCZ6ToiLvN27wVnbz3lmYY8KrMi8eZKeEF_mM5bh4eDQ_yZ6EsMG4LGrGHmcnOa9YTTk7za6XLSDQGlRETiPZbIadtBGpFrYutuBlf4OcRWHwO7OTHTIWfXUepEW9jAZsDOi3iS2yrgFkYZ2KO0BLot6h6E3fHRVXSRaStbQK_NPskZZdgGfj9yz78enj8uLL7PLq8-Li_HKmGM_jTNOyKCqa12QFpFmpmiiqKaekLnFFSVrJgXCsNONK1jyXjGPNm7pRlLJVhYuz7OXBt-9cEGNoQaRQeE1zyvJELA5E4-RG9N5spb8RThrxt-D8WkgfjepAMMwazDTRjGmqFJEF1oBLqUkj9YrL5PVh3G1YbaFRKR8vu4npdMWaVqzdTpS8LMuiTAZvRgPvfg0QotiaoKDrpAU37M9NcVXllO7P_eof9P7bjdRapgsYq13aV-1NxXl6DrzMy6JK1PweKo0GtkalF6ZNqk8EbyeCxES4jms5hCAW37_9P3v1c8q-PmJbkF1sg-uGaJwNU5AeQOVdCB70XcgEi32D3KYh9g0ixgZJshfHP-hOdNsRxR9J1Qu3</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2039842462</pqid></control><display><type>article</type><title>The effect of adjuvant chemotherapy on survival in Korean patients with node negative T1c, triple negative breast cancer</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><source>Public Library of Science (PLoS)</source><creator>Lim, Seung Taek ; Park, Chan Heun ; Kim, Sung Yong ; Nam, Seok Jin ; Kang, Eun Young ; Moon, Byung-In ; Lee, Hyouk Jin ; Jeon, Ye Won ; Gwak, Hongki ; Suh, Young Jin</creator><creatorcontrib>Lim, Seung Taek ; Park, Chan Heun ; Kim, Sung Yong ; Nam, Seok Jin ; Kang, Eun Young ; Moon, Byung-In ; Lee, Hyouk Jin ; Jeon, Ye Won ; Gwak, Hongki ; Suh, Young Jin</creatorcontrib><description>The present study investigated the prognostic role of adjuvant systemic chemotherapy in patients with node negative, T1c triple negative breast cancer (TNBC) from a nationwide cohort. In addition, the prognostic effect between 3 different chemotherapy regimens were compared in node-negative T1c TNBC patients by subgroup analysis.
From the Korean breast cancer registry database, 1,151 T1c node negative TNBC patients were included in this study. Patients were categorized into four treatment groups according to chemotherapy regimen: (1) no chemotherapy, (2) adriamycin plus cyclophosphamide (AC), (3) adriamycin/epirubicin plus cyclophosphamide plus 5-FU (FAC/FEC), and (4) cyclophosphamide plus 5-FU plus methotrexate (CMF). Overall survival (OS) was evaluated between each patient group.
Of the 1,151 T1c node negative TNBC patients, 1,006 received adjuvant chemotherapy, while 145 received no chemotherapy. Among the patients receiving adjuvant chemotherapy the distribution of regimens was: 586 AC, 168 FAC/FEC (126 FAC, 42 FEC), and 252 CMF. The mean follow-up time of the full study cohort was 87.98 ± 33.56 months (range = 6-192 months). Patients in the no chemotherapy group showed significantly worse OS compared to each chemotherapy regimen group. However, when OS was compared between each chemotherapy regimen, no significant difference was found.
This study showed that adjuvant systemic chemotherapy improved OS in T1c node negative TNBC patients, regardless of chemotherapy between AC, FAC/FEC, and CMF regimens.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0197523</identifier><identifier>PMID: 29768496</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Adjuvant chemotherapy ; Breast cancer ; Breast Neoplasms - diagnosis ; Breast Neoplasms - drug therapy ; Breast Neoplasms - mortality ; Cancer ; Cancer therapies ; Chemotherapy ; Chemotherapy, Adjuvant ; Cyclophosphamide ; Cyclophosphamide - administration & dosage ; Cyclophosphamide - therapeutic use ; Doxorubicin - administration & dosage ; Doxorubicin - therapeutic use ; Drug therapy ; Drug Therapy, Combination - methods ; Epirubicin ; Epirubicin - administration & dosage ; Epirubicin - therapeutic use ; Female ; Fluorouracil - administration & dosage ; Fluorouracil - therapeutic use ; Genetic aspects ; Hospitals ; Humans ; Mastectomy ; Medical prognosis ; Medical screening ; Medicine ; Medicine and Health Sciences ; Methotrexate ; Methotrexate - administration & dosage ; Methotrexate - therapeutic use ; Middle Aged ; Oncology ; Patient outcomes ; Patients ; Prognosis ; Registries ; Republic of Korea - epidemiology ; Retrospective Studies ; Studies ; Subgroups ; Surgery ; Survival ; Survival Analysis ; Thyroid gland ; Triple Negative Breast Neoplasms - diagnosis ; Triple Negative Breast Neoplasms - drug therapy ; Triple Negative Breast Neoplasms - mortality ; University colleges</subject><ispartof>PloS one, 2018-05, Vol.13 (5), p.e0197523-e0197523</ispartof><rights>COPYRIGHT 2018 Public Library of Science</rights><rights>2018 Lim et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2018 Lim et al 2018 Lim et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c692t-f453374281be1dbc81c4f49418507417422e190cf69ca892a690f9d8dc446b703</citedby><cites>FETCH-LOGICAL-c692t-f453374281be1dbc81c4f49418507417422e190cf69ca892a690f9d8dc446b703</cites><orcidid>0000-0001-8281-198X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5955535/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5955535/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,2096,2915,23845,27901,27902,53766,53768,79343,79344</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29768496$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lim, Seung Taek</creatorcontrib><creatorcontrib>Park, Chan Heun</creatorcontrib><creatorcontrib>Kim, Sung Yong</creatorcontrib><creatorcontrib>Nam, Seok Jin</creatorcontrib><creatorcontrib>Kang, Eun Young</creatorcontrib><creatorcontrib>Moon, Byung-In</creatorcontrib><creatorcontrib>Lee, Hyouk Jin</creatorcontrib><creatorcontrib>Jeon, Ye Won</creatorcontrib><creatorcontrib>Gwak, Hongki</creatorcontrib><creatorcontrib>Suh, Young Jin</creatorcontrib><title>The effect of adjuvant chemotherapy on survival in Korean patients with node negative T1c, triple negative breast cancer</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>The present study investigated the prognostic role of adjuvant systemic chemotherapy in patients with node negative, T1c triple negative breast cancer (TNBC) from a nationwide cohort. In addition, the prognostic effect between 3 different chemotherapy regimens were compared in node-negative T1c TNBC patients by subgroup analysis.
From the Korean breast cancer registry database, 1,151 T1c node negative TNBC patients were included in this study. Patients were categorized into four treatment groups according to chemotherapy regimen: (1) no chemotherapy, (2) adriamycin plus cyclophosphamide (AC), (3) adriamycin/epirubicin plus cyclophosphamide plus 5-FU (FAC/FEC), and (4) cyclophosphamide plus 5-FU plus methotrexate (CMF). Overall survival (OS) was evaluated between each patient group.
Of the 1,151 T1c node negative TNBC patients, 1,006 received adjuvant chemotherapy, while 145 received no chemotherapy. Among the patients receiving adjuvant chemotherapy the distribution of regimens was: 586 AC, 168 FAC/FEC (126 FAC, 42 FEC), and 252 CMF. The mean follow-up time of the full study cohort was 87.98 ± 33.56 months (range = 6-192 months). Patients in the no chemotherapy group showed significantly worse OS compared to each chemotherapy regimen group. However, when OS was compared between each chemotherapy regimen, no significant difference was found.
This study showed that adjuvant systemic chemotherapy improved OS in T1c node negative TNBC patients, regardless of chemotherapy between AC, FAC/FEC, and CMF regimens.</description><subject>Adjuvant chemotherapy</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - diagnosis</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - mortality</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>Chemotherapy, Adjuvant</subject><subject>Cyclophosphamide</subject><subject>Cyclophosphamide - administration & dosage</subject><subject>Cyclophosphamide - therapeutic use</subject><subject>Doxorubicin - administration & dosage</subject><subject>Doxorubicin - therapeutic use</subject><subject>Drug therapy</subject><subject>Drug Therapy, Combination - methods</subject><subject>Epirubicin</subject><subject>Epirubicin - administration & dosage</subject><subject>Epirubicin - therapeutic use</subject><subject>Female</subject><subject>Fluorouracil - administration & dosage</subject><subject>Fluorouracil - therapeutic use</subject><subject>Genetic aspects</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Mastectomy</subject><subject>Medical prognosis</subject><subject>Medical screening</subject><subject>Medicine</subject><subject>Medicine and Health Sciences</subject><subject>Methotrexate</subject><subject>Methotrexate - administration & dosage</subject><subject>Methotrexate - therapeutic use</subject><subject>Middle Aged</subject><subject>Oncology</subject><subject>Patient outcomes</subject><subject>Patients</subject><subject>Prognosis</subject><subject>Registries</subject><subject>Republic of Korea - epidemiology</subject><subject>Retrospective Studies</subject><subject>Studies</subject><subject>Subgroups</subject><subject>Surgery</subject><subject>Survival</subject><subject>Survival Analysis</subject><subject>Thyroid gland</subject><subject>Triple Negative Breast Neoplasms - diagnosis</subject><subject>Triple Negative Breast Neoplasms - drug therapy</subject><subject>Triple Negative Breast Neoplasms - mortality</subject><subject>University colleges</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><sourceid>DOA</sourceid><recordid>eNqNk1-L1DAUxYso7rr6DUQDgig4Y9KmafMiLIt_BhcWdPQ1ZNKbaYZOUpN03P32ZpzuMpV9kDw03PzOSXKam2XPCZ6ToiLvN27wVnbz3lmYY8KrMi8eZKeEF_mM5bh4eDQ_yZ6EsMG4LGrGHmcnOa9YTTk7za6XLSDQGlRETiPZbIadtBGpFrYutuBlf4OcRWHwO7OTHTIWfXUepEW9jAZsDOi3iS2yrgFkYZ2KO0BLot6h6E3fHRVXSRaStbQK_NPskZZdgGfj9yz78enj8uLL7PLq8-Li_HKmGM_jTNOyKCqa12QFpFmpmiiqKaekLnFFSVrJgXCsNONK1jyXjGPNm7pRlLJVhYuz7OXBt-9cEGNoQaRQeE1zyvJELA5E4-RG9N5spb8RThrxt-D8WkgfjepAMMwazDTRjGmqFJEF1oBLqUkj9YrL5PVh3G1YbaFRKR8vu4npdMWaVqzdTpS8LMuiTAZvRgPvfg0QotiaoKDrpAU37M9NcVXllO7P_eof9P7bjdRapgsYq13aV-1NxXl6DrzMy6JK1PweKo0GtkalF6ZNqk8EbyeCxES4jms5hCAW37_9P3v1c8q-PmJbkF1sg-uGaJwNU5AeQOVdCB70XcgEi32D3KYh9g0ixgZJshfHP-hOdNsRxR9J1Qu3</recordid><startdate>20180516</startdate><enddate>20180516</enddate><creator>Lim, Seung Taek</creator><creator>Park, Chan Heun</creator><creator>Kim, Sung Yong</creator><creator>Nam, Seok Jin</creator><creator>Kang, Eun Young</creator><creator>Moon, Byung-In</creator><creator>Lee, Hyouk Jin</creator><creator>Jeon, Ye Won</creator><creator>Gwak, Hongki</creator><creator>Suh, Young Jin</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-8281-198X</orcidid></search><sort><creationdate>20180516</creationdate><title>The effect of adjuvant chemotherapy on survival in Korean patients with node negative T1c, triple negative breast cancer</title><author>Lim, Seung Taek ; Park, Chan Heun ; Kim, Sung Yong ; Nam, Seok Jin ; Kang, Eun Young ; Moon, Byung-In ; Lee, Hyouk Jin ; Jeon, Ye Won ; Gwak, Hongki ; Suh, Young Jin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c692t-f453374281be1dbc81c4f49418507417422e190cf69ca892a690f9d8dc446b703</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Adjuvant chemotherapy</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - diagnosis</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - mortality</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>Chemotherapy, Adjuvant</topic><topic>Cyclophosphamide</topic><topic>Cyclophosphamide - administration & dosage</topic><topic>Cyclophosphamide - therapeutic use</topic><topic>Doxorubicin - administration & dosage</topic><topic>Doxorubicin - therapeutic use</topic><topic>Drug therapy</topic><topic>Drug Therapy, Combination - methods</topic><topic>Epirubicin</topic><topic>Epirubicin - administration & dosage</topic><topic>Epirubicin - therapeutic use</topic><topic>Female</topic><topic>Fluorouracil - administration & dosage</topic><topic>Fluorouracil - therapeutic use</topic><topic>Genetic aspects</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Mastectomy</topic><topic>Medical prognosis</topic><topic>Medical screening</topic><topic>Medicine</topic><topic>Medicine and Health Sciences</topic><topic>Methotrexate</topic><topic>Methotrexate - administration & dosage</topic><topic>Methotrexate - therapeutic use</topic><topic>Middle Aged</topic><topic>Oncology</topic><topic>Patient outcomes</topic><topic>Patients</topic><topic>Prognosis</topic><topic>Registries</topic><topic>Republic of Korea - epidemiology</topic><topic>Retrospective Studies</topic><topic>Studies</topic><topic>Subgroups</topic><topic>Surgery</topic><topic>Survival</topic><topic>Survival Analysis</topic><topic>Thyroid gland</topic><topic>Triple Negative Breast Neoplasms - diagnosis</topic><topic>Triple Negative Breast Neoplasms - drug therapy</topic><topic>Triple Negative Breast Neoplasms - mortality</topic><topic>University colleges</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lim, Seung Taek</creatorcontrib><creatorcontrib>Park, Chan Heun</creatorcontrib><creatorcontrib>Kim, Sung Yong</creatorcontrib><creatorcontrib>Nam, Seok Jin</creatorcontrib><creatorcontrib>Kang, Eun Young</creatorcontrib><creatorcontrib>Moon, Byung-In</creatorcontrib><creatorcontrib>Lee, Hyouk Jin</creatorcontrib><creatorcontrib>Jeon, Ye Won</creatorcontrib><creatorcontrib>Gwak, Hongki</creatorcontrib><creatorcontrib>Suh, Young Jin</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lim, Seung Taek</au><au>Park, Chan Heun</au><au>Kim, Sung Yong</au><au>Nam, Seok Jin</au><au>Kang, Eun Young</au><au>Moon, Byung-In</au><au>Lee, Hyouk Jin</au><au>Jeon, Ye Won</au><au>Gwak, Hongki</au><au>Suh, Young Jin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The effect of adjuvant chemotherapy on survival in Korean patients with node negative T1c, triple negative breast cancer</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2018-05-16</date><risdate>2018</risdate><volume>13</volume><issue>5</issue><spage>e0197523</spage><epage>e0197523</epage><pages>e0197523-e0197523</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>The present study investigated the prognostic role of adjuvant systemic chemotherapy in patients with node negative, T1c triple negative breast cancer (TNBC) from a nationwide cohort. In addition, the prognostic effect between 3 different chemotherapy regimens were compared in node-negative T1c TNBC patients by subgroup analysis.
From the Korean breast cancer registry database, 1,151 T1c node negative TNBC patients were included in this study. Patients were categorized into four treatment groups according to chemotherapy regimen: (1) no chemotherapy, (2) adriamycin plus cyclophosphamide (AC), (3) adriamycin/epirubicin plus cyclophosphamide plus 5-FU (FAC/FEC), and (4) cyclophosphamide plus 5-FU plus methotrexate (CMF). Overall survival (OS) was evaluated between each patient group.
Of the 1,151 T1c node negative TNBC patients, 1,006 received adjuvant chemotherapy, while 145 received no chemotherapy. Among the patients receiving adjuvant chemotherapy the distribution of regimens was: 586 AC, 168 FAC/FEC (126 FAC, 42 FEC), and 252 CMF. The mean follow-up time of the full study cohort was 87.98 ± 33.56 months (range = 6-192 months). Patients in the no chemotherapy group showed significantly worse OS compared to each chemotherapy regimen group. However, when OS was compared between each chemotherapy regimen, no significant difference was found.
This study showed that adjuvant systemic chemotherapy improved OS in T1c node negative TNBC patients, regardless of chemotherapy between AC, FAC/FEC, and CMF regimens.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>29768496</pmid><doi>10.1371/journal.pone.0197523</doi><tpages>e0197523</tpages><orcidid>https://orcid.org/0000-0001-8281-198X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2018-05, Vol.13 (5), p.e0197523-e0197523 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_2039842462 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Free Full-Text Journals in Chemistry; Public Library of Science (PLoS) |
| subjects | Adjuvant chemotherapy Breast cancer Breast Neoplasms - diagnosis Breast Neoplasms - drug therapy Breast Neoplasms - mortality Cancer Cancer therapies Chemotherapy Chemotherapy, Adjuvant Cyclophosphamide Cyclophosphamide - administration & dosage Cyclophosphamide - therapeutic use Doxorubicin - administration & dosage Doxorubicin - therapeutic use Drug therapy Drug Therapy, Combination - methods Epirubicin Epirubicin - administration & dosage Epirubicin - therapeutic use Female Fluorouracil - administration & dosage Fluorouracil - therapeutic use Genetic aspects Hospitals Humans Mastectomy Medical prognosis Medical screening Medicine Medicine and Health Sciences Methotrexate Methotrexate - administration & dosage Methotrexate - therapeutic use Middle Aged Oncology Patient outcomes Patients Prognosis Registries Republic of Korea - epidemiology Retrospective Studies Studies Subgroups Surgery Survival Survival Analysis Thyroid gland Triple Negative Breast Neoplasms - diagnosis Triple Negative Breast Neoplasms - drug therapy Triple Negative Breast Neoplasms - mortality University colleges |
| title | The effect of adjuvant chemotherapy on survival in Korean patients with node negative T1c, triple negative breast cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T14%3A50%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20effect%20of%20adjuvant%20chemotherapy%20on%20survival%20in%20Korean%20patients%20with%20node%20negative%20T1c,%20triple%20negative%20breast%20cancer&rft.jtitle=PloS%20one&rft.au=Lim,%20Seung%20Taek&rft.date=2018-05-16&rft.volume=13&rft.issue=5&rft.spage=e0197523&rft.epage=e0197523&rft.pages=e0197523-e0197523&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0197523&rft_dat=%3Cgale_plos_%3EA538952537%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2039842462&rft_id=info:pmid/29768496&rft_galeid=A538952537&rft_doaj_id=oai_doaj_org_article_606d06f1f66f4cc1a30fe05af1dafb9a&rfr_iscdi=true |